How did RNAC's revenue and expenses shift in Q4 2024?

RNAC's revenue and expenses in Q4 2024 were characterized by a significant decline in operating income, with the company posting a substantial loss due to a sharp increase in expenses relative to its revenue. Here's a detailed analysis:

1. **Revenue Shift**:
- RNAC's total revenue for Q4 2024 was $39.11 million. This figure is crucial for understanding the company's financial performance during the period.
2. **Expense Shift**:
- The company's operating expenses were notably high, amounting to $7.09 million.
- This increase in operating expenses, when compared to the revenue, resulted in a negative operating margin of 93.83%.
- The high expenses include those for selling, general, and administrative activities, which also amounted to $7.09 million.
3. **Net Income Impact**:
- The significant gap between operating expenses and revenue led to a negative net income for the quarter.
- The negative net income, coupled with the high expenses, indicates that RNAC faced considerable financial challenges in Q4 2024.

In summary, RNAC's Q4 2024 financials show a company struggling with high expenses relative to its revenue, resulting in a substantial loss for the period. The company's focus on cost management will be critical for improving its financial health in the future.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|RNAC|RNAC.O|Cartesian Therapeutics|20240101-2024|Grant|638000|185|
|RNAC|RNAC.O|Cartesian Therapeutics|20240101-2024|Grant|561000|185|
|RNAC|RNAC.O|Cartesian Therapeutics|20240101-2024|Grant|174000|185|
|RNAC|RNAC.O|Cartesian Therapeutics|20240101-2024|Grant and Collaboration|5840000|185|
|RNAC|RNAC.O|Cartesian Therapeutics|20240101-2024|Grant and Collaboration|5840000|185|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|RNAC|RNAC.O|Cartesian Therapeutics|2023 Q4|-3114.7293398947904|-1.77658E8|185|
|RNAC|RNAC.O|Cartesian Therapeutics|2024 Q1|-162.30900613950053|-5.6824E7|185|
|RNAC|RNAC.O|Cartesian Therapeutics|2024 Q2|221.50698164573637|1.3836E7|185|
|RNAC|RNAC.O|Cartesian Therapeutics|2024 Q3|-168.64030215507665|-2.4183E7|185|

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|Operating Expenses|market_code|
|---|---|---|---|---|---|---|---|
|RNAC|RNAC.O|Cartesian Therapeutics|2023 Q4|-50.78297112235784|8266000||185|
|RNAC|RNAC.O|Cartesian Therapeutics|2024 Q1|-1.6503873358033008|5840000||185|
|RNAC|RNAC.O|Cartesian Therapeutics|2024 Q2|537.1689845684892|3.3445E7||185|
|RNAC|RNAC.O|Cartesian Therapeutics|2024 Q3|-94.09250496107464|387000||185|

|code|Ticker|Name|Date|Selling, General, and Administrative Expenses|Interest Expenses|Interest Expenses YoY|market_code|
|---|---|---|---|---|---|---|---|
|RNAC|RNAC.O|Cartesian Therapeutics|2023 Q4|2.2036E7|||185|
|RNAC|RNAC.O|Cartesian Therapeutics|2024 Q1|9450000|0|-100|185|
|RNAC|RNAC.O|Cartesian Therapeutics|2024 Q2|7027000|||185|
|RNAC|RNAC.O|Cartesian Therapeutics|2024 Q3|6562000|||185|